Management of Peripheral Edema in Patients with MET Exon 14-Mutated Non-small Cell Lung Cancer Treated with Small Molecule MET Inhibitors

Article Oncology

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

Xiuning Le et al.

Summary: Tepotinib demonstrated durable clinical activity in patients with METex14 skipping non-small cell lung cancer and consistent efficacy and manageable safety profile across different subgroups.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Review Oncology

Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review

Alexis Cortot et al.

Summary: MET exon 14 (MET ex14) skipping mutations are common in non-small cell lung cancer (NSCLC) patients. Four oral MET tyrosine kinase inhibitors (TKIs) are currently used for the treatment of MET ex14 skipping NSCLC. This review examines the safety profiles of these treatment options and provides guidance on clinical monitoring and management. Peripheral edema and nausea were the most reported treatment-related adverse events. These adverse events led to dose reductions or discontinuation in a portion of patients. Overall, MET TKIs are tolerable treatment options for patients with MET ex14 skipping NSCLC.

CLINICAL LUNG CANCER (2022)

添加到收藏夹

Article Oncology

Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: \nSafety, Efficacy, and Biomarkers

Yakun Wang et al.

Summary: This study aimed to confirm the recommended phase II dose (RP2D) of savolitinib in Chinese patients and explore the overall benefits in tumors with c-Met aberration. The results showed that response was observed in gastric cancer patients with MET amplification and target lesion shrinkage was observed in NSCLC patients with MET exon 14 skipping mutation.

ONCOLOGIST (2022)

添加到收藏夹

Article Oncology

Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program

Oliver Illini et al.

Summary: This study retrospectively analyzed the efficacy and safety of Capmatinib in patients with non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation. The results showed that Capmatinib demonstrated durable systemic and intracranial efficacy in this patient population, with a manageable safety profile.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

MO01.04 Management of Selected Adverse Events With Capmatinib: Institutional Experiences From the GEOMETRY Mono-1 Trial

K. Goodwin et al.

Journal of Thoracic Oncology (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Drug-induced peripheral oedema: An aetiology-based review

Berenger Largeau et al.

Summary: Drug-induced peripheral edema can occur through various mechanisms, such as vasodilatory edema, renal edema, lymphedema, and permeability edema. Different drugs may cause different types of peripheral edema, which may be underestimated and misdiagnosed, leading to inappropriate prescribing.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)

添加到收藏夹

Article Oncology

Capmatinib in Japanese patients with MET exon 14 skipping-mutated or MET-amplified advanced NSCLC: GEOMETRY mono-1 study

Takashi Seto et al.

Summary: Preplanned analysis of 45 Japanese patients showed that capmatinib was effective and well-tolerated in patients with MET Delta ex14/MET-amplified NSCLC, with consistent results compared to the overall population.

CANCER SCIENCE (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Savolitinib: First Approval

Anthony Markham

Summary: Savolitinib, a MET inhibitor developed for various cancers including NSCLC, recently received approval in China for patients with MET exon 14-skipping alterations. This milestone approval was based on pivotal phase II trial results.

DRUGS (2021)

添加到收藏夹

Article Oncology

Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study

Hiroshi Sakai et al.

Summary: Tepotinib demonstrated robust and durable clinical efficacy in Japanese patients with advanced NSCLC harboring MET exon 14 skipping, identified by either liquid or tissue biopsy. The main adverse events, blood creatinine increase and peripheral edema, were manageable.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology